Evidence map›Paper›PMID 41743381›Full record

ReviewTherapeutic advances in medical oncology2026

The relationship between genetic mutations and organ metastasis in non-small cell lung cancer.

Haiying Xue, Yuzhu Chen, Fei Qi, Kaixuan Chen, Xiaolin Liu, Muxin Zhang, Ziyuan Gao, Shanshan Cai, Tianbo Gao, Tongmei Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Haiying XueSchool of Medicine, Sun Yat-sen University, Shenzhen, China.
Yuzhu ChenDepartment of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID https://orcid.org/0009-0002-6784-1907
Fei QiDepartment of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID https://orcid.org/0000-0002-4853-2845
Kaixuan ChenHealth Science Center, Ningbo University, Ningbo, China.
Xiaolin LiuDepartment of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Muxin ZhangDepartment of Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Ziyuan GaoSchool of Medicine, Xi'an Jiaotong University, Xi'an, China.
Shanshan CaiDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, England LA1 4YG, UK.
Tianbo GaoDepartment of Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
Tongmei ZhangDepartment of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 9 Beiguan Street, Tongzhou District, Beijing 101149, China.ORCID https://orcid.org/0000-0003-4271-3773

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer is among the most prevalent cancers worldwide, with its high metastatic potential driving poor prognosis and mortality. Advances in molecular testing and high-throughput sequencing have highlighted the roles of driver genes (EGFR, ALK, KRAS) and key non-driver genes (TP53, STK11, KEAP1) in NSCLC metastasis. These mutations influence tumor invasiveness, drug resistance, and organ-specific metastatic patterns-EGFR and ALK mutations favor brain metastasis, KRAS mutations are linked to bone, liver, and multiple lung metastases, while TP53, STK11, and KEAP1 mutations increase multi-organ metastatic risk. This review summarizes the associations between genetic mutations and metastatic sites, explores underlying molecular mechanisms, and discusses mutation-based risk prediction and personalized therapeutic strategies. With multi-omics integration and further clinical research, genetic profiling may become a key tool for guiding metastasis prevention, early intervention, and treatment optimization in NSCLC.

Indexed as

circulating tumor cells (CTCs)genetic mutationsnon-small cell lung cancerorgan-specific metastasispre-metastatic niche (PMN)

Identifiers

PMID41743381
PMCPMC12929888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.